NeoGenomics has received expanded coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for RaDaR ST monitoring of response to immune checkpoint inhibitor therapy in patients with late-stage solid tumors.
Immunotherapy continues to transform treatment across numerous cancer types. However, assessing response can present unique challenges. Patients may experience pseudoprogression, delayed response, or mixed response patterns that make conventional imaging difficult to interpret and can complicate treatment decisions.
RaDaR ST provides clinicians with personalized, longitudinal ctDNA monitoring that may offer earlier molecular insight into treatment response dynamics while complementing imaging and clinical evaluation.
This expanded Medicare coverage represents a meaningful step toward improving access to molecular monitoring for patients receiving immunotherapy and supports more informed treatment decisions throughout the care journey.